Cardiomyopathy natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(14 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Cardiomyopathy}} {{CMG}}
{{Cardiomyopathy}}  
{{CMG}}; {{AE}}  [[User:Lina Ya'qoub|Lina Ya'qoub, MD]]; {{EdzelCo}}


Please help WikiDoc by adding more content here. It's easy!  Click  [[Help:How_to_Edit_a_Page|here]] to learn about editing.
==Overview==
Cardiomyopathy will continue to progressively worsen, unless intervened on. As the function of the heart deteriorates, symptoms of [[heart failure]] become apparent. On the other hand, defects in ion channels and [[hypertrophic cardiomyopathy]] can present with fatal [[arrhythmias]] and sudden cardiac death without the preceding symptoms of [[Congestive heart failure|heart failure]]. In general, complications and sequelae of cardiomyopathy include [[heart failure]], [[arrythmia]], [[thromboembolic disease]], and [[sudden cardiac death]]. Prognosis of patients depends on the etiology of the cardiomyopathy and the initiation of management, whether medical, surgical or device therapy. Patients with cardiomyopathy are usually treated with medical treatment similar to heart failure patients, although some patients do not respond well to medications and continue to have worsening heart function, which may require [[heart transplant]] eventually. Those patients at high risk for fatal [[arrhythmias]] and sudden cardiac death should receive device therapy with [[Implantable cardioverter defibrillator|implantable cardioverter defibrillator (ICD)]] or [[Cardiac resynchronization therapy|cardiac resynchronization therapy (CRT)]].
 
== Natural History ==
* The symptoms of cardiolyopathy usually develop secondary to a predisposing factor and an underlying cause and start with symptoms such as [[fatigue]], [[fever]], and [[shortness of breath]].
* Cardiomyopathy will continue to progressively worsen, unless intervened on.<ref name="pmid24976920">{{cite journal |vauthors=Sisakian H |title=Cardiomyopathies: Evolution of pathogenesis concepts and potential for new therapies |journal=World J Cardiol |volume=6 |issue=6 |pages=478–94 |date=June 2014 |pmid=24976920 |pmc=4072838 |doi=10.4330/wjc.v6.i6.478 |url=}}</ref><ref name="pmid28355432">{{cite journal |vauthors=Al-Khatib SM, Fonarow GC, Joglar JA, Inoue LYT, Mark DB, Lee KL, Kadish A, Bardy G, Sanders GD |title=Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy: A Meta-analysis |journal=JAMA Cardiol |volume=2 |issue=6 |pages=685–688 |date=June 2017 |pmid=28355432 |doi=10.1001/jamacardio.2017.0630 |url=}}</ref>


==Overview==
Cardiomyopathy will continue to progressively worsen, unless intervened on. Complications and sequelae of cardiomyopathy include [[heart failure]], [[arrythmia]], [[thromboembolic disease]], and [[sudden cardiac death]].
==Complications==
==Complications==
Cardiomyopathy gets worse unless treated. The most likely complications are;
Cardiomyopathy gets worse unless treated. The most likely complications are:<ref name="pmid20141097">{{cite journal |vauthors=Wexler RK, Elton T, Pleister A, Feldman D |title=Cardiomyopathy: an overview |journal=Am Fam Physician |volume=79 |issue=9 |pages=778–84 |date=May 2009 |pmid=20141097 |doi= |url=}}</ref>
 
* [[Heart failure]]
* [[Heart failure]]
* [[Arrythmia]]  
* [[Arrythmia]]  
Line 14: Line 17:
* [[Sudden cardiac death]]
* [[Sudden cardiac death]]


== Prognosis ==
Prognosis of patients depends on the etiology of the cardiomyopathy and the initiation of management, whether medical, surgical or device therapy:
* Patients with cardiomyopathy are usually treated with medical treatment similar to [[heart failure]] patients, although some patients do not respond well to medications and continue to have worsening heart function, which may require heart transplant eventually.
* Those patients at high risk for fatal arrhythmias and sudden cardiac death should receive device therapy with [[Implantable cardioverter defibrillator|implantable cardioverter defibrillator (ICD)]] or [[Cardiac resynchronization therapy|cardiac resynchronization therapy (CRT)]].<ref name="pmid24976920" /><ref name="pmid28355432" /><ref name="pmid20141097" />
<div align="left">
<div align="left">
<gallery heights="175" widths="175">
<gallery heights="175" widths="175">
Line 30: Line 37:
[[Category:Up-To-Date cardiology]]
[[Category:Up-To-Date cardiology]]
[[Category:Disease]]
[[Category:Disease]]
{{WH}}
{{WS}}
{{WS}}

Latest revision as of 03:27, 27 October 2023

Cardiomyopathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cardiomyopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Guidelines

2023 ESC Guideline Recommendations

2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy

Case Studies

Case #1

Cardiomyopathy natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cardiomyopathy natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiomyopathy natural history, complications and prognosis

CDC on Cardiomyopathy natural history, complications and prognosis

Cardiomyopathy natural history, complications and prognosis in the news

Blogs on Cardiomyopathy natural history, complications and prognosis

Directions to Hospitals Treating Cardiomyopathy

Risk calculators and risk factors for Cardiomyopathy natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Lina Ya'qoub, MD; Edzel Lorraine Co, DMD, MD[2]

Overview

Cardiomyopathy will continue to progressively worsen, unless intervened on. As the function of the heart deteriorates, symptoms of heart failure become apparent. On the other hand, defects in ion channels and hypertrophic cardiomyopathy can present with fatal arrhythmias and sudden cardiac death without the preceding symptoms of heart failure. In general, complications and sequelae of cardiomyopathy include heart failure, arrythmia, thromboembolic disease, and sudden cardiac death. Prognosis of patients depends on the etiology of the cardiomyopathy and the initiation of management, whether medical, surgical or device therapy. Patients with cardiomyopathy are usually treated with medical treatment similar to heart failure patients, although some patients do not respond well to medications and continue to have worsening heart function, which may require heart transplant eventually. Those patients at high risk for fatal arrhythmias and sudden cardiac death should receive device therapy with implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT).

Natural History

  • The symptoms of cardiolyopathy usually develop secondary to a predisposing factor and an underlying cause and start with symptoms such as fatigue, fever, and shortness of breath.
  • Cardiomyopathy will continue to progressively worsen, unless intervened on.[1][2]

Complications

Cardiomyopathy gets worse unless treated. The most likely complications are:[3]

Prognosis

Prognosis of patients depends on the etiology of the cardiomyopathy and the initiation of management, whether medical, surgical or device therapy:

References

  1. 1.0 1.1 Sisakian H (June 2014). "Cardiomyopathies: Evolution of pathogenesis concepts and potential for new therapies". World J Cardiol. 6 (6): 478–94. doi:10.4330/wjc.v6.i6.478. PMC 4072838. PMID 24976920.
  2. 2.0 2.1 Al-Khatib SM, Fonarow GC, Joglar JA, Inoue L, Mark DB, Lee KL, Kadish A, Bardy G, Sanders GD (June 2017). "Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy: A Meta-analysis". JAMA Cardiol. 2 (6): 685–688. doi:10.1001/jamacardio.2017.0630. PMID 28355432. Vancouver style error: initials (help)
  3. 3.0 3.1 Wexler RK, Elton T, Pleister A, Feldman D (May 2009). "Cardiomyopathy: an overview". Am Fam Physician. 79 (9): 778–84. PMID 20141097.

Template:WS